Evaluation of Weekly Paclitaxel plus Carboplatin Followed by Anthracycline Chemotherapy on the Neoadjuvant Treatment of Patients with Triple-Negative Breast Cancer

Conclusion The combination of neoadjuvant chemotherapy with wP + wCb before anthracycline chemotherapy can be tolerated by patients with triple-negative breast cancer. Complete pathologic response rates were comparable with those historically seen. Careful selection of patients is fundamental as this regimen is associated with a high incidence of hematologic toxicity.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research